Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
| Stock | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| ONONOn Holding AG | Caspar Felix CoppettiExecutive Officer & Co-CEO | $1.99M | Added | |||
| Bought 65,000 Class A shares at $30.6737 weighted avg (range $30.57–$30.78) on Aug 14, 2026. Same-day purchase as Co-CEO Olivier Bernhard. ONON dropped 20%+ post-Q2 earnings miss before this buy. Post-transaction holdings: 2,440,855 shares. No 10b5-1 plan. | ||||||
| ONONOn Holding AG | Olivier BernhardExecutive Officer | $1.99M | Added | |||
| Bought 65,000 Class A shares at $30.6737 weighted avg (range $30.57–$30.78) on Aug 14, 2026. Same-day purchase as Co-CEO Coppetti. Post-transaction holdings: 5,228,184 shares. Cluster buy signal: both founders purchasing simultaneously. | ||||||
| BFLYButterfly Network, Inc. | Louise S. PhanstielDirector | $999K | Added | |||
| Bought 115,200 Class A shares at $8.6763 weighted avg (range $8.49–$8.865) on Aug 14, 2026, via The Phanstiel Trust. Post-transaction: 300,461 indirect + 390,952 direct shares. No 10b5-1 plan. | ||||||
| MLABMesa Laboratories, Inc. | Siddhartha KadiaPresident and CEO | $800K | Added | |||
| Acquired 7,093 shares at $112.80/share on Aug 13, 2026 — NOTE: this was a privately negotiated purchase from Board Chair John Sullivan, NOT an open-market transaction. Purchased via Anjou Parekh Lifetime Access Trust (spouse as trustee). | ||||||
| ASNDAscendis Pharma A/S | Jean Jacques BienaiméDirector | $493K | Added | |||
| Two open-market purchases on Aug 14: 1,100 shares at $245.85 avg ($270,435) and 900 shares at $246.91 avg ($222,219). Total 2,000 shares at ~$246.38 avg. Post-transaction: 2,900 direct shares. No 10b5-1 plan. | ||||||
| REZIResideo Technologies, Inc. | Joshua Peter FosterSVP, General Counsel & Corporate Secretary | $315K | Added | |||
| Bought 15,317 shares at approximately $20.58 avg in open-market transaction. Cluster buy alongside CEO Thomas Surran within same week. Resideo is a home comfort and security technology company. | ||||||
| REZIResideo Technologies, Inc. | Thomas A SurranPresident and CEO | $307K | Added | |||
| Bought 15,000 shares at $20.46 weighted avg (range $20.41–$20.47) on Aug 14, 2026. Post-transaction: 338,573 direct shares. Cluster buy: CEO + SVP GC both purchasing near identical prices. | ||||||
| ENHAEnhanced Group Inc. | Apeiron Investment Group Ltd.10% Owner | $296K | Added | |||
| Apeiron Investment Group (European family office) bought 150,000 shares at approximately $1.97 avg. Currently −17.3% below buy price. Small-cap, limited liquidity — treat as speculative. | ||||||
Scanned EDGAR Form 4 filings filed August 17–18, 2026 (48-hour window; most transactions executed Aug 13–14). 8 qualifying buys (≥ $250K, transaction type P) across 6 companies, totalling $7.2M.
On Holding (ONON) dominates this scan with the largest combined value (~$4.0M) and the most conviction signal: both founders and Co-CEOs purchased on August 14, the exact same day, after ONON dropped 20%+ on Q2 results that missed expectations. Classic "founders buy the dip" when they have superior knowledge of the business trajectory. ONON is currently +1.2% above the purchase price with the stock stabilizing.
Resideo Technologies (REZI) shows a CEO + SVP cluster buy, with both executives transacting independently at nearly identical price levels ($20.46–$20.58). Resideo is an IoT and home comfort/security technology company that recently underwent leadership transition; this coordinated buying often signals internal conviction about upcoming catalysts.
Butterfly Network (BFLY) director Phanstiel committed ~$1M through her family trust at $8.68 — a high-conviction buy for a medical device AI ultrasound company near its recent lows. Now 3.7% in the green.
Ascendis Pharma (ASND) director Bienaimé is adding to a small existing position, buying rare disease biotech shares around $246 — notable given the company's strong pipeline momentum.
Mesa Labs (MLAB) purchase was a privately negotiated transaction (CEO buying from Board Chair, not open market) — flagged for transparency. Less of a market-signal than standard open-market buys.
ENHA is currently underwater 17% since the Apeiron buy — small-cap risk with limited liquidity. Treat with caution.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.